Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

NIH

Sponsor class

Conditions

Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Hodgkin Lymphoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Decitabine and Cedazuridine
BIOLOGICAL: Nivolumab
PROCEDURE: Positron Emission Tomography

Sponsor

National Cancer Institute (NCI)